Related Experiment Video
Updated: Jul 25, 2025
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma
Jonhoi Smith1, Melvin Field1,2, Kiminobu Sugaya1
1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Abstract:
Glioblastoma (GBM) is an aggressive and incurable primary brain tumor that harbors therapy-resistant cancer stem cells (CSCs). Due to the limited effectiveness of conventional chemotherapies and radiation treatments against CSCs, there is a critical need for the development of innovative therapeutic approaches. Our previous research revealed the significant expression of embryonic stemness genes, NANOG and OCT4, in CSCs, suggesting their role in enhancing cancer-specific stemness and drug resistance. In our current study, we employed RNA interference (RNAi) to suppress the expression of these genes and observed an increased susceptibility of CSCs to the anticancer drug, temozolomide (TMZ). Suppression of NANOG expression induced cell cycle arrest in CSCs, specifically in the G0 phase, and it concomitantly decreased the expression of PDK1. Since PDK1 activates the PI3K/AKT pathway to promote cell proliferation and survival, our findings suggest that NANOG contributes to chemotherapy resistance in CSCs through PI3K/AKT pathway activation. Therefore, the combination of TMZ treatment with RNAi targeting NANOG holds promise as a therapeutic strategy for GBM.
Insights
Targeting NANOG in glioblastoma cancer stem cells (CSCs) with RNA interference enhances temozolomide (TMZ) effectiveness. Suppressing NANOG induces cell cycle arrest and overcomes drug resistance, offering a new therapeutic strategy for this aggressive brain tumor.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with therapy-resistant cancer stem cells (CSCs).
- Conventional treatments show limited effectiveness against GBM CSCs, necessitating novel therapeutic strategies.
- Embryonic stemness genes NANOG and OCT4 are highly expressed in CSCs, correlating with stemness and drug resistance.
Purpose of the Study:
- To investigate the role of NANOG and OCT4 in GBM CSCs' drug resistance.
- To evaluate the therapeutic potential of suppressing NANOG and OCT4 in GBM.
Main Methods:
- RNA interference (RNAi) was used to suppress NANOG and OCT4 expression in GBM CSCs.
- The effect of gene suppression on CSC susceptibility to temozolomide (TMZ) was assessed.
- Cell cycle analysis and expression levels of key signaling molecules were examined.
Main Results:
- Suppression of NANOG expression increased GBM CSCs' sensitivity to TMZ.
- NANOG suppression induced cell cycle arrest in the G0 phase.
- PDK1 expression decreased upon NANOG suppression, suggesting PI3K/AKT pathway inhibition.
Conclusions:
- NANOG plays a critical role in GBM CSCs' resistance to chemotherapy.
- NANOG promotes GBM CSC survival and proliferation via PI3K/AKT pathway activation.
- Combining TMZ with RNAi targeting NANOG is a promising therapeutic approach for glioblastoma.
More Related Videos
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:56Treatment Resistant Cancers